- Das 7h s 22h
GLP-1 medications slow gastric emptying and affect gut motility, which can cause nausea, diarrhoea, constipation, and bloating
Furthermore, over 80% of the published animal data originates from a single laboratory in Croatia, lacking independent validation, and the senior author holds commercial patents on the peptide
BioMed Pharmacother (2005) 59:3807
Backed by a wealth of research, including 70 similar clinical trials and 80,000+ studies, this powerful ingredient has built a strong credibility for itself
avoid diuretics | | Oral bisphosphonates (alendronate) | Gastric emptying delay may reduce already-low bioavailability | Efficacy loss possible | Minor | Take bisphosphonate on empty stomach 30 min before triple agonist | Prescribing Framework for Triple Agonists No FDA-approved labeling for retatrutide existed as of July 2025, but phase 2 and phase 3 trial protocols establish a de facto dosing framework that clinicians in early-access or clinical-trial settings follow